By focusing primarily on CD34+CD38low/- stem and progenitor subsets, we provided evidence supporting a consistent and standardized approach to evaluating metabolic status in liquid biopsy for AML, minimizing the impact of interindividual variations in different marker expressions. This evidence concerns the gene CD34 and acute myeloid leukemia.